Drug Search Results
More Filters [+]

BNT-166

Alternative Names: BNT-166, BNT166, BNT 166, BNT166a
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

The mpox vaccine program BNT166 is part of BioNTech’s efforts to develop novel prophylactic vaccines for a range of infectious diseases with a high medical need, including indications that are disproportionally prevalent in lower-income countries. Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3. BioNTech is aiming to develop a prophylactic mRNA-based mpox vaccine with a favorable safety profile that can be manufactured at scale. (Sourced from: https://investors.biontech.de/news-releases/news-release-details/biontech-and-cepi-announce-partnership-advance-mrna-mpox-vaccine)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioNTech
Company Location: MAINZ 2M 55131
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BNT-166

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title